Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report for the Scottish Medicines Consortium (SMC)
Cisplatin and gemcitabine for neoadjuvant treatment of adults with muscle invasive bladder cancer (MIBC): SMC2880

About this release

This release by Public Health Scotland (PHS) uses information from the National SACT dataset.

This work was requested by the Scottish Medicines Consortium (SMC) to support their decision-making processes. Durvalumab in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by durvalumab as monotherapy adjuvant treatment after radical cystectomy, for the treatment of adults with resectable muscle invasive bladder cancer (MIBC) is being assessed for use by NHS Scotland (SMC2880).

It was only possible to reliably identify patients in 2 out of 3 cancer networks in NHS Scotland due to data availability. Therefore, the aim of this work was to capture real-world evidence (RWE) from West of Scotland Cancer Network (WoSCAN) and the South East Scotland Cancer Network (SCAN) on the use of cisplatin and gemcitabine for neoadjuvant treatment of adults with MIBC. Details of the presumptions made to identify this cohort are described in Section 2.3.1. of the main report. This work will enable SMC members to assess the relevance of information, provided as part of the assessment process for SMC2880, to patients in Scotland.

The objectives of this work were to:

• Determine the number of patients receiving cisplatin and gemcitabine for neoadjuvant treatment of MIBC.
• Describe the baseline characteristics of patients receiving cisplatin and gemcitabine for neoadjuvant treatment of MIBC.
• Determine the number of patients who, after receiving cisplatin and gemcitabine for neoadjuvant treatment of MIBC, went on to have a radical cystectomy.
• Provide information on subsequent systemic anti-cancer therapy (SACT) following cisplatin and gemcitabine for neoadjuvant treatment of MIBC and radical cystectomy.